Harrow (NASDAQ:HROW) Share Price Breaks Above 50 Day Moving Average – Time to Sell?

Harrow, Inc. (NASDAQ:HROW – Get Free Report) shares crossed above its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $30.31 and traded as high as $32.52. Harrow shares last traded at $32.16, with a volume of 865,224 shares.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Leerink Partners assumed coverage on shares of Harrow in a report on Wednesday, September 9th. They set an “outperform” rating and a $45.00 target price for the company. Weiss Ratings raised shares of Harrow from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, November 13th. BTIG Research restated a “buy” rating and set a $63.00 price target on shares of Harrow in a research report on Wednesday, November 11th. Zacks Research downgraded Harrow from a “hold” rating to a “strong sell” rating in a research report on Tuesday, November 3rd. Finally, Wall Street Zen raised Harrow from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $66.20.

View Our Latest Stock Analysis on HROW

Harrow Stock Down 5.4%

The company has a debt-to-equity ratio of 10.15, a current ratio of 2.29 and a quick ratio of 2.12. The stock’s fifty day moving average is $30.14 and its 200-day moving average is $37.20.

Harrow (NASDAQ:HROW – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.19 by $0.06. Harrow had a negative return on equity of 69.81% and a negative net margin of 9.39%. The company had revenue of $99.30 million during the quarter, compared to analyst estimates of $98.59 million. Equities research analysts anticipate that Harrow, Inc. will post -0.50 EPS for the current year.

Institutional Trading of Harrow

Hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. acquired a new position in Harrow in the second quarter valued at about $116,373,000. Luxor Capital Group LP increased its position in shares of Harrow by 22.0% during the first quarter. Luxor Capital Group LP now owns 1,119,400 shares of the company’s stock valued at $39,470,000 after acquiring an additional 201,859 shares during the last quarter. Bamco Inc. NY raised its stake in shares of Harrow by 26.0% in the 3rd quarter. Bamco Inc. NY now owns 1,019,932 shares of the company’s stock valued at $31,414,000 after acquiring an additional 210,582 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of Harrow by 56.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock valued at $20,428,000 after acquiring an additional 208,972 shares during the period. Finally, Jupiter Topco LLC purchased a new stake in shares of Harrow in the 2nd quarter valued at approximately $24,596,000. 72.76% of the stock is owned by institutional investors and hedge funds.

About Harrow

(Get Free Report)

Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.

Recommended Stories

Receive News & Ratings for Harrow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow and related companies with MarketBeat.com's FREE daily email newsletter.